Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
10/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
10/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
09/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

14/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
16/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
13/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
13/12/14	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
21/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
10/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
09/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
09/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+6.17%	+13.26%	+33.13%	-1.04%	70.75B
UCB	-13.51%	-10.70%	+17.04%	+172.20%	54.35B
SAMSUNG BIOLOGICS CO.,LTD.	+3.25%	+52.70%	+52.70%	+52.70%	47.19B
CSL LIMITED	-3.69%	+6.44%	-54.56%	-54.12%	42.48B
BIOGEN INC.	-0.62%	+3.64%	+64.19%	-21.60%	30.91B
INCYTE CORPORATION	-3.23%	+5.40%	+58.59%	+94.94%	25.76B
MODERNA, INC.	+6.29%	+1.58%	+80.16%	-51.19%	21.62B
INNOVENT BIOLOGICS, INC.	-1.31%	-3.22%	-11.17%	+151.59%	19.91B
SWEDISH ORPHAN BIOVITRUM AB	-0.13%	+3.10%	+69.03%	+129.42%	16.9B
Average	-0.74%	+3.10%	+34.35%	+52.54%	36.65B
Weighted average by Cap.	-0.89%	+4.01%	+29.13%	+46.53%

Employees

Sector